Approved Asthma Therapy Omalizumab Reduces SLE Disease Activity, Phase 1b Trial Finds
Omalizumab is well-tolerated and reduces disease activity in patients with systemic lupus erythematosus, a Phase 1b trial shows.
0 Comments
Approved Asthma Therapy Omalizumab Reduces SLE Disease Activity, Phase 1b Trial Finds
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed